Strictly for in-vitro research and laboratory use
BPC-157 has a molecular weight of approximately 1,419 Da on the larger end for nasal mucosal absorption which may constrain bioavailability compared to smaller peptides like Semax (which weighs 604 Da and is specifically designed for nasal delivery).8 Who nasal delivery may be relevant for (research context): Neurological or brain-adjacent applications Patients for whom injection is contraindicated Situations requiring rapid onset with non-invasive administration Research protocols studying nose-to-brain peptide pathways What to be realistic about: No peer-reviewed human trials on intranasal BPC-157 exist as of 2026 Nasal absorption of BPC-157 is less predictable than for smaller peptides Dosing standardisation for nasal BPC-157 is not established Consult a licensed provider before considering this route Peptide Delivery Method Comparison Table How to Choose the Right BPC-157 Delivery Method for Your Goal Matching the delivery method to the clinical goal is the single most important decision in BPC-157 therapy
Systematic review (sports medicine) Vasireddi et al
Biogenic Foods Description Description CAS Number: N/A (research blend) Molecular Formula: N/A (research blend) Molecular Weight: N/A (research blend) Form: Lyophilized Powder Quantity: 5mg & 10mg vial Purity: 98% (HPLC Verified) Dosing Information Cagrinilintide is typically administered once weekly via subcutaneous injection, with doses ranging from 1 mg to 12 mg depending on clinical indication and patient response
It is intended for research applications, often in academic or clinical settings exploring the peptides effect on neurotransmitter levels, stress, and chronic pain
However, the conservative approach is waiting until skeletal maturity and the early 20s when growth plates are fully closed and endocrine systems are mature
